Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: Evidence for an indirect mechanism

Journal of Molecular and Cellular Cardiology

Volumn 28, Issue 2, 1996, Pages 341-350

  Clarke, Brendan ^a,b   Wyatt, Katrina M ^a   McCormack, James G ^a  

^a HERIOT WATT UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Acetyl CoA; Beta oxidation; Metabolic modulation; Mitochondria; Pyruvate dehydrogenase; Pyruvate dehydrogenase kinase; Pyruvate dehydrogenase phosphate phosphatase; Ranolazine

Indexed keywords

ACETYL COENZYME A; ALBUMIN; CORONARY VASODILATING AGENT; DICHLOROACETIC ACID; GLUCOSE; PALMITIC ACID; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE PHOSPHATASE; RANOLAZINE;

ANIMAL TISSUE; ARTICLE; ENZYME ACTIVITY; FATTY ACID OXIDATION; GLUCOSE OXIDATION; HEART HEMODYNAMICS; HEART MITOCHONDRION; HEART MUSCLE METABOLISM; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0029996458     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1996.0032     Document Type: Article

References (35)

1. ALLELY MC, ALPS BJ, 1988. The effects of the novel antianginal agent ranolazine (i.d.) in a canine model of transient myocardial ischaemia. (Abstract). Br J Pharmacol 93: 246P.
2. ALLELY MC, ALPS BJ, 1990. Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion. Br J Pharmacol 96: 5-6.
3. +] and pH in a canine model of transient myocardial ischaemia. Biochem Soc Trans 15: 1057-1058.
4. 1-adrenoceptors in the rat left ventricle by ischaemia and acyl carnitines; protection by ranolazine. J Cardiovasc Pharmacol 21: 869-873.
5. BOUVY T, ROUSSEAU MF, COCCO G, CHERON P, WILLIAM GJ, DETRY JMR, 1993. Improvement in exercise tolerance and left ventricular filling dynamics in patients with angina pectoris with the novel metabolic modulator, ranolazine. Acta Cardiol 48: 98-99.
6. BRODERICK TL, QUINNEY HA, BARKER CC, LOPASCHUK GD, 1993. Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of ischemia is accompanied by a stimulation of glucose oxidation. Circulation 87: 972-981.
7. BURKHOFF D, WEISS RG, SCHULMAN SP, KALIL-FILHO R, WANNENBERG T, GERSTENBLITH G, 1991. Influence of metabolic substrate on rat heart function and metabolism at different coronary flows. Am J Physiol 261: H741-H750.
8. CLARKE B, SPEDDING M, PATMORE L, MCCORMACK JG, 1993. Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase. Br J Pharmacol 109: 748-750.
9. CLARKE B, WYATT KM, MCCORMACK JG, 1994. Ranolazine increases active pyruvate dehydrogenase (PDH) in perfused normoxic rat hearts. (Abstract). J Mol Cell Cardiol 26: CLXXIV.
10. COCCO G, ROUSSEAU MF, BOUVY T, CHERON P, WILLIAMS G, DETRY JM, POULEUR H, 1992. Effects of a new metabolic modulator, Ranolazine, on exercise tolerance in Angina Pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmocol 20: 131-138.
11. CORKEY BE, 1988. Analysis of acyl-Coenzyme A esters in biological samples. Meth Enzymol 166: 55-70.
12. DATORRE SD, CREER MH, POGWIZD SM, CORR PB, 1991. Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. J Mol Cell Cardiol 23 [Suppl. I]: 11-22.
13. FERRANDON P, PASCAL J-C, ARMSTRONG JM, 1988. Protective effects of the novel anti-ischaemic agent ranolazine (RS-43285) in the reperfused rat heart. (Abstract) Br J Pharmacol 93: 247P.
14. GRALINSKI MR, BLACK SC, KILGORE KS, CHOU KY, MCCORMACK JG, LUCCHESI BR, 1994. Cardioprotective effects ofranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res 28: 1231-1237.
15. HUTTER JF, PIPER HM, SPIECKERMANN PG, 1985. Effects of fatty acid oxidation on efficiency of energy production in rat heart. Am J Physiol 249: H723-H728.
16. JACKSON S, TURNBULL DM, 1994. Defects of fatty acid oxidation. In: Darley-Usmar V and Shapira A, eds. Mitochondria: DNA, Proteins and Disease. Portland Press: London, 201-220.
17. KOBAYASHI K, NEELY JR, 1983. Effects of ischaemia and reperfusion on pyruvate dehydrogenase activity in isolated rat hearts. J Mol Cell Cardiol 15: 359-367.
18. LOPASCHUK GD, WAMBOLT RB, BARR RL, 1993. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Therap 264: 135-144.
19. LOPASCHUK GD, BELKE DD, GAMBLE J, ITOI T, SCHONEKESS BO, 1994. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1213: 263-276.
20. LYSIAK W, LILLY K, DILISA F, TOTH P, BIEBER LL, 1988. Quantitation of the effect of L-carnitine on the levels of acid-soluble short-chain acyl-CoA and CoASH in rat heart and liver mitochondria. J Biol Chem 263: 1151-1156.
21. 2+ ions in the regulation of in tramitochondrial metabolism in the heart. Biochem J 218: 235-247.
22. MCCORMACK JG, DENTON RM, 1989. Influence of calcium ions on mammalian intramitochondrial dehydrogenases. Meth Enzymol 174: 95-118.
23. 2+ and pyruvate in the regulation of rat heart pyruvate dehydrogenase activity. Biochem J 202:419-427.
24. MCCORMACK JG, HALESTRAP AP, DENTON RM, 1990. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev 70: 391-425.
25. MCCORMACK JG, BARR RL, WOLFF AA, LOPASCHUK GD, 1995. Ranolazine stimulates glucose oxidation in isolated working rat hearts. Circulation, in press.
26. MCVEIGH JJ, LOPASCHUK GD, 1990. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemiC hearts. Am J Physiol 259: H1079-H1085.
27. OPIE LH, 1991. Fuels: carbohydrates and lipids. In: Opie LH, ed. The Heart: Physiology and Metabolism. Raven Press: New York, 208-246.
28. POULEUR H, HUE L, HARLOW BJ, ROUSSEAU MF, 1989. Metabolic pathways modulation: a new approach to treat myocardial ischemia. (Abstract). Circulation 80 [Suppl. II]: 11-52.
29. a kinase and synergistic inhibition by pyruvate and ADP. J Biol Chem 254: 7191-7196.
30. RANDLE PJ, 1986. Fuel selection in animals. Biochem Soc Trans 14: 799-806.
31. ROUSSEAU MF, VISSER FG, BAX JJ, DUBREY S, Cocco G, POULEUR H, HARRIS SR, WOLFF AA, 1994. Ranolazine: anti-anginal therapy with a novel mechanism, a controlled comparison versus atenolol. (Abstract). Eur Heart J 15 [Suppl.]: 95.
32. SADDIK M, GAMBLE J, WITTERS LA, LOPASCHUK GD, 1993. Acetyl CoA carboxylase regulation of fatty acid oxidation in the heart. J Biol Chem 268: 25836-25845.
33. SMITH WB, CHRYSANT S, GARLAND WT, PARKER TS, WALPOLE HT, MOKATRIN A, GENNEVOIS D, PEPINE CJ, 1995. A multicenter controlled trial of a novel metabolic active compound (ranolazine) in chronic stable angina patients. Am Coll Cardiol, in press.
34. WYATT KM, SKENE C, VEITCH K, HUE L, MCCORMACK JG, 1995. The anti-anginal agent ranolazine is a weak inhibitor of the respiratory Complex I, but with greater potency in broken or uncoupled than in coupled mitochondria. Biochem Pharmacol, in press.
35. YEAMAN SJ, HUTCHESON ET, ROCHE TE, PETTIT FH, BROWN JR, REED LJ, WATSON DC, DIXON GH, 1978. Sites of phosphorylation on pyruvate dehydrogenase from bovine kidney and heart. Biochemistry 17: 2364-2370.